Health Condition 1: 4- Measurement and Monitoring Health Condition 2: H401- Open-angle glaucoma
Conditions
Interventions
Intervention1: Ripasudil
: eye drop Ripasudil hydrochloride 0.4%
dose : Twice daily for 3 months
Control Intervention1: Eye drop Timolol: eye drop timolol 0.5%
dose: twice daily for 3 months
Sponsors
Dr Sowparnika A B
Eligibility
Inclusion criteria
Inclusion criteria: 1. Newly detected POAG / OHT. 2. POAG will be defined as: a. IOP > 21 mmHg on atleast 2 occasions, atleast 24 has apart. b. Optic nerve head showing CDR > 0.61 with significant thinning of the neuroretinal rim: or a CDR asymmetry of 0.2 > between 2 eyes. c. Open angles on gonioscopy. d. Automated visual field testing showing changes corresponding with the optic disc changes. 3. OHT will be defined as: • IOP > 21 mmHg on atleast 2 occasions, 24 hrs apart. • Open angles on gonioscopy • Normal optic disc and visual field tests 4. Patients willing to participate in the study given a written informed consent and comply with the followup schedule.
Exclusion criteria
Exclusion criteria: 1. Patients with POAG / OHT having IOP > 30 mmHg. 2. Patient with PACG and others secondary glaucoma. 3. Patient underwent surgery on the inner eye 4. Patient who changed glaucoma treatment after ripasudil administration
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| measurement of IOPTimepoint: day 14, 1 month, 2months and 3 months | — |
Secondary
| Measure | Time frame |
|---|---|
| safety and tolerability of Ripasudil in comparison with TimololTimepoint: day 14, 1 month, 2 months and 3 months | — |
Countries
India
Contacts
Public ContactDr Anitha S Maiya
JJMMC
Outcome results
None listed